Ivermectine Teva

Ivermectin, the active ingredient in Ivermectine Teva, is an antiparasitic (macrocyclic lactone) presented as an oral dosage form for systemic use. It is employed to treat a range of parasitic infections, including river blindness, strongyloidiasis, lymphatic filariasis, scabies, lice infestation and other intestinal helminthiases.

GNH USA supplies Ivermectine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality, regulatory compliance and reliable delivery across global markets for a broad range of therapeutic needs.

Ivermectin is an antiparasitic agent used to treat several helminthic and ectoparasitic infections. - Onchocerciasis (river blindness): reduces microfilarial load and helps prevent ocular and skin disease. - Strongyloidiasis: eliminates intestinal larvae and prevents chronic infection. - Lymphatic filariasis (in combination therapy): contributes to parasite clearance when used with other agents. - Scabies: kills the Sarcoptes scabiei mite, relieving itching and skin lesions. - Pediculosis (lice infestation): eradicates head lice and nits. - Other intestinal helminth infections: treats a variety of nematode infections such as ascariasis and hookworm.

Ivermectin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset or queasiness. - Diarrhea: loose stools, usually self‑limiting. - Dizziness: transient light‑headedness or vertigo. - Pruritus: skin itching, often related to parasite die‑off.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurological events: seizures, ataxia or altered consciousness. - Hepatic injury: elevated liver enzymes or hepatitis.

Before prescribing Ivermectin, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: use only if the potential benefit outweighs the risk, as data are limited. - Breastfeeding: assess risk versus benefit; small amounts may be excreted in milk. - Concomitant CNS depressants: monitor for enhanced central nervous system effects. - Renal or hepatic impairment: dose adjustment may be required; evaluate organ function. - Known hypersensitivity: avoid in patients with documented allergy to ivermectin or related compounds. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Ivermectin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., clarithromycin, verapamil): can increase ivermectin exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): monitor INR as ivermectin may potentiate anticoagulant effect. - Other antiparasitics (e.g., albendazole): assess for additive neurotoxicity. - CNS depressants (benzodiazepines, alcohol): observe for enhanced sedation or dizziness.